Abstract Details
| Yuval Karmon, MD (Multiple Sclerosis Clinic) | No disclosure on file |
| Robert Zivadinov, MD, PhD, FAAN (Buffalo Neuroimaging Analysis Center) | The institution of Dr. Zivadinov has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS. The institution of Dr. Zivadinov has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Omnicuris. The institution of Dr. Zivadinov has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Myrobalan. Dr. Zivadinov has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi. Dr. Zivadinov has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for EMD Serono. Dr. Zivadinov has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Bristol Myers Squibb. The institution of Dr. Zivadinov has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen. |
| Bianca Weinstock-Guttman, MD (Department of Neurology, University At Buffalo) | Dr. Weinstock-Guttman has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen. Dr. Weinstock-Guttman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech. Dr. Weinstock-Guttman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis . Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genzyme &Sanofi. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen . Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bayer. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Horizon. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Weinstock-Guttman has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Weinstock-Guttman has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen. Dr. Weinstock-Guttman has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Janssen. Dr. Weinstock-Guttman has received personal compensation in the range of $0-$499 for serving as a Reviewer with NIH. |
| Karen Marr, BA | No disclosure on file |
| No disclosure on file | |
| Kresimir Dolic, MD (University Hospital Split) | No disclosure on file |
| No disclosure on file | |
| Ellen Carl, MS (The Jacobs Neurological Institute) | No disclosure on file |
| Toby I. Gropen, MD (University of Alabama At Birmingham) | Dr. Gropen has nothing to disclose. |
| No disclosure on file | |
| Elad Levy | No disclosure on file |
| Adnan Siddiqui | Adnan Siddiqui has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Abbott Laboratories, Acandis, Asahi Intecc Co. Ltd., Canon Medical Systems USA, Inc., Carotix Medical, LLC, CerebrovaKP, Cerenovus, Contego Medical, Inc., Cordis, Endostream Medical, Ltd (recently sold to Kaneka), FreeOx Biotech, SL, Hyperfine Operations, Inc., Imperative Care , InspireMD, Ltd., IRRAS AB, Medtronic, Minnetronix Neuro, Inc., MMI, Peijia Medical, Penumbra, Inc. Perflow Medical, Ltd., Piraeus Medical, Inc., Prometheus Therapeutics, Inc., Q'Apel Medical, Inc., Serenity Medical, Inc., Shockwave Medical, Inc., Stryker Neurovascular., Synchron Australia Pty Ltd., Tegus Medical, GmbH, T.G. Medical, Inc., Terumo Neuro (Formerly MicroVention), Unity Medical, Inc. Vastrax, LLC, Vesalio, Viz.ai, Inc., WL Gore. Adnan Siddiqui has stock in 3N Endovascular, Adona Medical, Inc., Basecamp Vascular SAS, Bend IT Technologies, Ltd., BlinkTBI, Inc, Borvo Medical, Inc., CerebrovaKP, Code Zero Medical, Inc., Cognition Medical, Collavidence, Inc., Contego Medical, Inc., CVAID Ltd., CygnusMed, E8, Inc., Endostream Medical, Ltd (Sold 2025 to Kaneka), FreeOx Biotech, SL, Galaxy Therapeutics, Inc., Hyperion Surgical, Inc., Imperative Care, Inc., InspireMD, Ltd., Instylla, Inc., IRRAS, AB, Launch NY, Inc., Neurolutions, Inc., Neurovascular Diagnostics, Inc., NeXtGen Biologics, Peijia Medical, PerFlow Medical, Ltd., Physician X, LLC, Piraeus Medical, Inc., Prometheus Therapeutics, Inc., PUMA Venture Capital Fund I, LP, Q'Apel Medical, Inc., QAS.ai, Inc., Radical Catheter Technologies, Inc., ReNiva, Inc., Rist Neurovascular, Inc. (Purchased 2020 by Medtronic), Sense Diagnostics, Inc., Serenity Medical, Inc., Silk Road Medical, Sim & Cure, Spinnaker Medical, Inc., Stent'Up, Synchron, Inc., Tegus Medical, GmbH, T.G. Medical, Inc., Tulavi Therapeutics, Inc., Vastrax, LLC,, Viseon, Inc., Viz.ai, Whisper Medical, Inc., Willow Medtech, Inc. . Adnan Siddiqui has received research support from National PI/Steering Committees: Cerenovus EXCELLENT and ARISE II Trial; Medtronic ARTISSE IDE, SWIFT PRIME, VANTAGE, EMBOLISE and SWIFT DIRECT Trials; Terumo Neuro (formerly MicroVention) FRED Trial & CONFIDENCE Study; MUSC POSITIVE Trial; Penumbra 3D Separator Trial, COMPASS Trial, INVEST Trial, MIVI neuroscience EVAQ Trial; Rapid Medical SUCCESS Trial; InspireMD C-GUARDIANS IDE Pivotal Trial; . The institution of Adnan Siddiqui has received research support from Current Research Grants: Co-I for NSF 2304388 STTR Phase II: An AI-Enhanced Angiographic System to Guide Endovascular Treatment of Intracranial Aneurysms; Co-PI NIH OT2NS129366 / Medical University of South Carolina StrokeNet Thrombectomy Endovascular Platform (STEP); PI for Brain Aneurysm Foundation study titled Exploring the Relationship between Imaging- and Blood-Based Aneurysm Biomarkers and the Pathobiology of the Aneurysm Wall; PI for University of Cincinnati / NINDS FASTEST: rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time Trial;. Adnan Siddiqui has received intellectual property interests from a discovery or technology relating to health care. |